Biopharma Corporate Strategy – Senior Analyst

Immix Biopharma, Inc. (NADSAQ : IMMX)

Biopharma Corporate Strategy – Senior Analyst

Location : Los Angeles, CA / Hybrid

Full time position

How You Will Contribute

• Responsible for corporate, investor and board presentations
• Responsible for financial and operating models
• Existing Pipeline – Using literature and commercial database research, participate in determining development strategy for existing pipeline
• New Pipeline – Conduct literature and commercial database research to evaluate opportunities to expand pipeline of human therapeutics

Skills and Experience We Look For

Prior healthcare investment banking and / or equity research internship, or work experience (~1-2 years) preferred

Education : BS / BA, or MD / PhD / PharmD / science degree

Our 3 Core Values

Rewards at Immix

Our people are our greatest asset, and supporting their well-being is an essential part of delivering on our mission and impacting the lives of patients. Putting this belief into practice means offering strong compensation and benefits.

Compensation will be commensurate with experience. Our compensation package also includes an annual bonus based on company goals and an equity grant. Health insurance and 401k included.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq : IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. NXC-201 is being evaluated in the U.S. Phase 1b / 2 trial NEXICART-2 (NCT06097832) as well as the ex-U.S. study NEXICART-1 (NCT04720313). NXC-201 has demonstrated no neurotoxicity of any kind in AL Amyloidosis, supporting expansion into select immune-mediated diseases. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at and